Medical Technologies Claim the New VC Interest

Author: Dinesh H Patel
Managing Director, vSpring
Personalized Medicine is a key trend in life science investing, and is being driven by two converging factors. The first being the completion of the human genome project which led to the cataloging of human genes and the second being an informed consumer base that demands more information and more participation in their own health care decisions. Personalized Medicine on the whole is comprised of three related technological approaches - predictive, personalized, and preventative/ prognostic technologies. Predictive technologies include molecular diagnostics and whole genome sequencing that determine an individual’s disease susceptibility or pinpoint where along a disease course an individual may be prior to the symptomatic presentation of the disease. A pioneering example of such predictive technologies is the BRCAnalysis diagnostic test, which assesses a women’s lifetime risk of developing breast and ovarian cancer based on their genetic profile. Personalized technologies include therapies targeted to the exact molecular mechanisms associated with, or causative for, a disease, such as Herceptin for certain forms of breast cancer and Selzentry which is a targeted treatment indicated for patients infected with a specific form of HIV. The third technological approach is preventative/prognostic technologies, which are aimed at assessing how aggressively a disease might proceed, based on an individual’s genetic make-up and the genetic cause of disease.

While still in the early days of technology development, prognostic technologies will enable a doctor to determine whether a disease is more likely to progress at a slow rate or at a fast rate. For example, if a disease is more likely to progress at a fast rate, then the physician can prescribe a more aggressive treatment plan such as surgery, or if the disease is more likely to proceed at a slow rate, then prognostic technologies will prevent unnecessary surgeries which in turn will reduce the costs of health care.

Molecular diagnostics, next-generation sequencing, and single-cell/single-molecule analysis are emerging technologies in the Personalized Medicine investment sector. In particular, Molecular Diagnostics that are based on novel disease causing mutations such as Single Nucleotide Polymorphism (SNPs) or Copy Number Variation (CNVs) will be critical to developing targeted drugs (pharmacogenetics) and will enable the earlier identification of disease and disease susceptibility.

The key areas of innovation that the more successful molecular diagnostic companies are incorporating include the use of genetic information related to the individual patient, and opportunities that integrate good science with the ability to interact online. The other area of innovation is on the operating side of the business. Specifically, there are opportunities to differentiate a business by adopting innovative operating strategies that are less capital intensive – such as molecular diagnostics versus therapeutic drug development – and those that are more capital efficient by outsourcing non-core, commoditized activities and not incurring fixed overhead when possible.

Focus on financing as the value-generating milestone, and interactions with the customer are key factors for any startup in this line to grow. Most entrepreneurs are cautiously optimistic by nature, necessarily optimistic that they will be successful, but at the same time are cautious about taking more money than is necessary to achieve the critical value-creating results. Entrepreneurs should bereft themselves “over-funding” their companies, as that tends to result in solving non-urgent, non-critical problems that detract from solving the urgent and critical ones. Secondly, entrepreneurs in the life sciences should talk with customers early and often. The laboratory is quite a distance from the end-user of a life science technology. An example of this is a primary care physician as the end-user of a diagnostic test. It is critical to talk to the customer in order to determine what the customer sees as "value" and not what the entrepreneur or start-up company might see as a "quality product."
Previous  article
Next article
Write your comment now

Email    Password: 
Don't have SiliconIndia account? Sign up    Forgot your password? Reset
Reader's comments(3)
1: From: Mrs. Mary David

This mail may be a surprise to you because you did not give me the permission to do so and neither do you know me but before I tell you about myself I want you to please forgive me for sending this mail without your permission. I am writing this letter in confidence believing that if it is the will of God for you to help me and my family, God almighty will bless and reward you abundantly. I need an honest and trust worthy person like you to entrust this huge transfer project unto.

My name is Mrs. Mary David, The Branch Manager of a Financial Institution. I am a Ghanaian married with 3 kids. I am writing to solicit your assistance in the transfer of US$7,500,000.00 Dollars. This fund is the excess of what my branch in which I am the manager made as profit last year (i.e. 2010 financial year). I have already submitted an annual report for that year to my head office in Accra-Ghana as I have watched with keen interest as they will never know of this excess. I have since, placed this amount of US$7,500,000.00 Dollars on an Escrow Coded account without a beneficiary (Anonymous) to avoid trace.

As an officer of the bank, I cannot be directly connected to this money thus I am impelled to request for your assistance to receive this money into your bank account on my behalf. I agree that 40% of this money will be for you as a foreign partner, in respect to the provision of a foreign account, and 60% would be for me. I do need to stress that there are practically no risk involved in this. It's going to be a bank-to-bank transfer. All I need from you is to stand as the original depositor of this fund so that the fund can be transferred to your account.

If you accept this offer, I will appreciate your timely response to me. This is why and only reason why I contacted you, I am willing to go into partnership investment with you owing to your wealth of experience, So please if you are interested to assist on this venture kindly contact me back for a brief discussion on how to proceed.

All correspondence must be via my private E-mail ( for obvious security reasons.

Best regards,
Mrs. Mary David.
Posted by: mary lovely david - Monday 26th, September 2011
2: Hi my dear,
My name is Mounace, i would like to establish a true relationship with you in one love. please send email to me at ( i will reply to you with my picture and tell you more about myself. thanks and remain blessed for me,
Your new friend Mounace
Posted by: mounace love love - Thursday 09th, June 2011
3: Human genome sequencing has definitely given way to various innovative technologies. But at the same time it is also important that the benefits of it should be communicated to the end user in the most efficient ways. The know how of the techniques of molecular biology is required to be understood by the patients for an informed decision making, by clinicains to advice for the test timely and even the sales and marketing team to communicate it to the doctors. Medico marketing is highly efficient in pharma companies having inhouse medical depts but diagnostic industry still needs to be more aggressive in this aspect as future is there for them..
Posted by: shalini Ratan - Wednesday 24th, February 2010
More articles
by Kaushal Mehta - Founder & CEO, Motif Inc..
The retail industry is witnessing an increased migration of customers from traditional brick and mortar retail to E-commerce (online retail)...more>>
by Samir Shah - CEO, Zephyr .
You probably do because you are on the phone with them! For all of you working in some technical management capacity here in Silicon Valley,...more>>
by Raj Karamchedu - Chief Operating Officer, Legend Silicon .
These days are a mixed bag for me. Of late I have been considering "doing something bigger and better," in my life, perhaps seriously though...more>>
by Madhavi Vuppalapati - CEO of Prithvi Information Solutions .
IT Services Rise of Tier II companies The Indian IT outsourcing industry is going through very exciting phase in its business life...more>>
by Bhaskar Bakthavatsalu- Country Manager, India and SAARC of Check Point Software Technologies.
Data loss occurs every day through corporate email. In fact, given the sheer number of emails an organization sends every day, data loss inc...more>>